CCL2 chemokine as a potential biomarker for prostate cancer: A pilot study

Cancer Research and Treatment

Volumn 47, Issue 2, 2015, Pages 306-312

  Tsaur, Igor ^a   Noack, Anika ^a   Makarevic, Jasmina ^a   Oppermann, Elsie ^a   Waaga Gasser, Ana Maria ^b   Gasser, Martin ^b   Borgmann, Hendrik ^a   Huesch, Tanja ^a   Gust, Kilian ^a   Reiter, Michael ^a   Schilling, David ^a   Bartsch, Georg ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Biological markers; Chemokine CCL2; Chemokines; Diagnosis; Prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; FRACTALKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTATE SPECIFIC ANTIGEN; RANTES; STROMAL CELL DERIVED FACTOR 1;

AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84928548857     PISSN: 1598-2998     EISSN: 2005-9256     Source Type: Journal    
DOI: 10.4143/crt.2014.015     Document Type: Article

References (25)

1. Gumulec J, Sochor J, Hlavna M, Sztalmachova M, Krizkova S, Babula P, et al. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep. 2012;27:831-41.
2. Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, et al. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013;13: 1667-71.
3. Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 2011;90:97-100.
4. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed). 2009;14:540-51.
5. Lin TH, Liu HH, Tsai TH, Chen CC, Hsieh TF, Lee SS, et al. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta. 2013;1830:4917-27.
6. Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611-9.
7. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol. 2002;2:175-84.
8. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer--much more than directing cell movement. Int J Dev Biol. 2004;48:489-96.
9. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:181-5.
10. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 2004;14: 195-200.
11. Wedel SA, Raditchev IN, Jones J, Juengel E, Engl T, Jonas D, et al. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep. 2008;1:257-62.
12. Wittekind C, Meyer HJ, Bootz F. UICC: TNM Klassifikation maligner Tumoren. 6. Auflage. Berlin: Springer; 2002.
13. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29: 1228-42.
14. Waugh DJ, Wilson C, Seaton A, Maxwell PJ. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci. 2008;13:4595-604.
15. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98:1652-8.
16. Tsaur I, Noack A, Waaga-Gasser AM, Makarevic J, Schmitt L, Kurosch M, et al. Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomark. 2011;10:195-204.
17. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, et al. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010;10:599.
18. Izhak L, Wildbaum G, Weinberg U, Shaked Y, Alami J, Dumont D, et al. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol. 2010;184:1092-101.
19. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311-8.
20. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, et al. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol. 2012;180:1008-16.
21. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73:573-81.
22. Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, et al. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol. 2008;134:1181-9.
23. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008;14:7790-7.
24. Wang Q, Diao X, Sun J, Chen Z. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol. 2013;31:312-7.
25. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008;68:442-52.